NCT06995573 - A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

September 30, 2026

Conditions

Alzheimer Disease

Interventions

DRUG

NSC001

rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor

OTHER

Placebo

matching placebo to NSC001

Trial Locations (6)

Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft GmbH, Salzburg

University Hospital Graz, Graz

Rostock University Medical Center, Rostock

Universitaetsmedizin Goettingen, Göttingen

Zentrum fuer klinische Forschung Dr. I. Schoell GmbH, Bad Homburg

Dynamikos GmbH Institut fuer Studien zur Psychischen Gesundheit, Mannheim